Table 1.

Studies included in the review

Authors	Publication year	Journal	Country	HCC-CC patients, n	HCC patients, n	MFCCC patients, n	Resected HCC-CC patients	Transplanted HCC-CC patients	Mean follow-up, months
Li et al. [21]	2018	Chin J Cancer Res	China	35	908	0	35	0	24
Chang et al. [22]	2017	Ann Transplant	Taiwan	11	290	0	0	11	23.9
Yoon et al. [23]	2016	J Gastrointest Surg	Korea	53	1,452	149	53	0	31.2
Lee et al. [24]	2014	Hepatobiliary Pancreat Dis Int	Korea	42	90	45	42	0	21.6
Kim et al. [25]	2014	Eur J Surg Oncol	Korea	30	0	77	30	0	22
Sapisochin et al. [26]	2014	Ann Surg	Spain	15	84	27	0	15	51
Yin et al. [27]	2012	Ann Surg Oncol	China	103	6,679	389	103	0	25
Sapisochin et al. [28]	2011	Liver Transpl	Spain	10	30	4	0	10	32
Lee et al. [29]	2011	J Clin Gastroenterol	Korea	30	60	60	30	0	18.3
Zuo et al. [30]	2007	Hepatobiliary Pancreat Dis Int	China	15	132	44	15	0	−
Tang et al. [31]	2006	J Gastrointest Surg	Japan	13	509	41	13	0	57.7
Lee et al. [4]	2006	Surg Today	Korea	33	832	78	33	0	46.8
Yano et al. [32]	2003	Jpn J Clin Oncol	Japan	26	1,093	53	26	0	33.2
Jarnagin et al. [2]	2002	Cancer	USA	21	27	23	21	0	38.3

This table shows the characteristics of all the comparative, retrospective analyses included in the systematic review. HCC-CC, hepatocholangiocarcinoma; HCC, hepatocellular carcinoma; MFCCC, mass-forming cholangiocarcinoma.